ELI LILLY AND COMPANY (LLY) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 47.86B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | Commercial Paper |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 142.28B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $47.86B | (m) | (m) | $142.28B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $39.37B | (m) | (m) | $116.58B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $40.87B | $0.00 | (m) | $112.48B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $40.87B | (m) | (m) | $114.94B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $34.18B | (m) | (m) | $100.92B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $34.50B | (m) | (m) | $89.39B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $28.53B | $4.34B | (m) | $78.71B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $29.05B | (m) | (m) | $75.61B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $23.73B | (m) | (m) | $71.87B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $24.56B | (m) | (m) | $63.94B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $18.32B | $6.19B | (m) | $64.01B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $17.92B | (m) | (m) | $57.92B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $18.16B | (m) | (m) | $54.81B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $18.88B | (m) | (m) | $53.16B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $14.74B | $1.50B | (m) | $49.49B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $14.14B | (m) | (m) | $47.46B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $14.69B | (m) | (m) | $47.06B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $15.15B | (m) | (m) | $46.92B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $15.35B | (m) | (m) | $48.81B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $15.52B | (m) | (m) | $48.19B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $14.74B | (m) | (m) | $47.81B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $16.20B | (m) | (m) | $46.84B | (m) |
| 2020-12-31 | (m) | (m) | (m) | $16.59B | $0.00 | (m) | $46.63B | (m) |
| 2020-09-30 | (m) | (m) | (m) | $16.33B | (m) | (m) | $43.95B | (m) |
| 2020-06-30 | (m) | (m) | (m) | $15.06B | (m) | (m) | $41.97B | (m) |
| 2020-03-31 | (m) | (m) | (m) | $13.98B | (m) | (m) | $41.10B | (m) |
| 2019-12-31 | (m) | (m) | (m) | $13.82B | $1.49B | (m) | $39.29B | (m) |
| 2019-09-30 | (m) | (m) | (m) | $13.66B | (m) | (m) | $37.89B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $13.72B | (m) | (m) | $38.67B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $13.61B | (m) | (m) | $38.01B | (m) |
| 2018-12-31 | (m) | (m) | (m) | $11.64B | $498.90M | (m) | $43.91B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $11.67B | (m) | (m) | $44.63B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $9.17B | (m) | (m) | $42.36B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $9.39B | (m) | (m) | $44.36B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $9.94B | $2.70B | (m) | $44.98B | (m) |
| 2017-09-30 | (m) | (m) | (m) | $9.93B | (m) | (m) | $43.01B | (m) |
| 2017-06-30 | (m) | (m) | (m) | $9.87B | (m) | (m) | $40.95B | (m) |
| 2017-03-31 | (m) | (m) | (m) | $7.64B | (m) | (m) | $37.62B | (m) |
| 2016-12-31 | (m) | (m) | (m) | $8.37B | $1.30B | (m) | $38.81B | (m) |
| 2016-09-30 | (m) | (m) | (m) | $8.71B | (m) | (m) | $37.59B | (m) |
| 2016-06-30 | (m) | (m) | (m) | $8.69B | (m) | (m) | $36.48B | (m) |
| 2016-03-31 | (m) | (m) | (m) | $7.48B | (m) | (m) | $34.69B | (m) |
| 2015-12-31 | (m) | (m) | (m) | $7.97B | $0.00 | $4.45B | $35.57B | (m) |
| 2015-09-30 | (m) | (m) | (m) | $8.07B | (m) | (m) | $36.30B | (m) |
| 2015-06-30 | (m) | (m) | (m) | $7.99B | (m) | (m) | $36.04B | (m) |
| 2015-03-31 | (m) | (m) | (m) | $7.42B | (m) | (m) | $35.65B | (m) |
| 2014-12-31 | (m) | (m) | (m) | $5.37B | $2.68B | (m) | $37.18B | (m) |
| 2014-09-30 | (m) | (m) | (m) | $5.29B | (m) | (m) | $34.65B | (m) |
| 2014-06-30 | (m) | (m) | (m) | $5.30B | (m) | (m) | $35.02B | (m) |
| 2014-03-31 | (m) | (m) | (m) | $5.26B | (m) | (m) | $34.76B | (m) |
| 2013-12-31 | (m) | (m) | $1.01B | $4.20B | (m) | (m) | $35.25B | (m) |
| 2013-09-30 | (m) | (m) | (m) | $4.26B | (m) | (m) | $33.97B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $4.29B | (m) | (m) | $33.23B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $4.43B | (m) | (m) | $32.30B | (m) |
| 2012-12-31 | (m) | (m) | $11.90M | $5.52B | (m) | (m) | $34.40B | (m) |
| 2012-09-30 | (m) | (m) | (m) | $5.51B | (m) | (m) | $34.32B | (m) |
| 2012-06-30 | (m) | (m) | (m) | $5.50B | (m) | (m) | $31.81B | (m) |
| 2012-03-31 | (m) | (m) | (m) | $5.40B | (m) | (m) | $32.24B | (m) |
| 2011-12-31 | (m) | (m) | $1.52B | $5.46B | (m) | (m) | $33.66B | (m) |
| 2011-09-30 | (m) | (m) | (m) | $5.45B | (m) | (m) | $33.04B | (m) |
| 2011-06-30 | (m) | (m) | (m) | $5.20B | (m) | (m) | $32.78B | (m) |
| 2011-03-31 | (m) | (m) | (m) | $5.13B | (m) | (m) | $31.70B | (m) |
| 2010-12-31 | (m) | (m) | $-18.20M | $6.77B | (m) | (m) | $31.00B | (m) |
| 2010-09-30 | (m) | (m) | (m) | $6.98B | (m) | (m) | $29.90B | (m) |
| 2010-06-30 | (m) | (m) | (m) | $6.86B | (m) | (m) | $27.72B | (m) |
| 2010-03-31 | (m) | (m) | (m) | $6.66B | (m) | (m) | $27.20B | (m) |
| 2009-12-31 | (m) | (m) | (m) | $6.63B | (m) | (m) | $27.46B | (m) |
| 2009-09-30 | (m) | (m) | (m) | $6.77B | (m) | (m) | $27.13B | (m) |
| 2009-06-30 | (m) | (m) | (m) | $6.69B | (m) | (m) | $26.93B | (m) |
| 2008-12-31 | (m) | (m) | (m) | $4.62B | (m) | (m) | $29.21B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |